Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a decline of 0.52% on January 19, 2025, underperforming the CSI 300 index by 0.57 percentage points, ranking 28th among 31 sub-industries [4]. - Notable performers within the pharmaceutical sub-industries included offline pharmacies (+2.39%) and blood products (+0.11%), while sectors such as medical R&D outsourcing (-1.77%) and vaccines (-1.10%) lagged behind [4]. - Takeda's new drug Oveporexton has received acceptance for its market application in China, targeting narcolepsy type 1 (NT1) and showing promising results in clinical trials [5]. Sub-industry Summary - Chemical Pharmaceuticals: No rating [3] - Traditional Chinese Medicine: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other Pharmaceuticals: Neutral [3]

此次获批的Lithonic™系统，其功能是用于向严重钙化狭窄部位(包括使用球囊无法完全扩张或支架无法 均匀扩张的钙化狭窄部位)释放高压声波进行预处理，其核心原理是利用电极在电解质溶液介质中发生 液电效应，在血管内精准释放高压治疗冲击波，直接作用于钙化病变进行修饰，并减少传统的钙化病变 治疗手段所引起的血管穿孔、无复流等并发症风险。 智通财经APP讯，蓝帆医疗(002382.SZ)公告，公司心脑血管事业部子公司Biosensors Interventional Technologies Pte. Ltd.的Lithonic™冠脉血管内冲击波治疗系统(简称"Lithonic™系统")获得欧盟CE认证。 ...

Core Viewpoint - The company, Bluestar Medical (002382.SZ), announced that its subsidiary, Biosensors Interventional Technologies Pte. Ltd., has received CE certification for the Lithonic™ coronary intravascular shockwave treatment system, which is designed to treat severely calcified narrow areas in blood vessels [1] Group 1 - The Lithonic™ system is intended for use in areas where balloon dilation is insufficient or stents cannot be evenly expanded due to calcification [1] - The system operates by releasing high-pressure shockwaves to pre-treat calcified lesions, utilizing the electrolysis effect in an electrolyte solution to precisely deliver the treatment [1] - This innovative approach aims to reduce the risk of complications associated with traditional calcified lesion treatments, such as vascular perforation and no-reflow phenomena [1]

每经AI快讯，1月19日，蓝帆医疗(002382.SZ)公告称，公司心脑血管事业部子公司Biosensors Interventional Technologies Pte. Ltd.的Lithonic™冠脉血管内冲击波治疗系统获得欧盟CE认证。该产品用 于严重钙化狭窄部位的预处理，能减少血管穿孔、无复流等并发症风险。此次认证不仅标志着该技术获 得国际认可，还巩固了公司在冠脉领域的技术优势，预计对公司经营发展产生积极影响。但医疗器械销 售受市场环境影响，投资者需谨慎投资。 ...